http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CH-588486-A5
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bba842fc4d37dfcaced1b55bc0c91c7c |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D457-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D519-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D457-04 |
| filingDate | 1973-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1977-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CH-588486-A5 |
| titleOfInvention | (13)-Bromo-beta-ergocryptine derivs. - prepd. from (13)-bromo-(9,10)-dihydro-lysergic acid |
| abstract | New beta-ergocryptine derivs. are of formula (I) and their acid-addn. salts: (where R1 is Me or i-Pr). Cpds. (I) are useful as medicaments (unspecified). They influence the EEG pattern of unnarcotised rats (extended waking phase, shortened classic sleep phase, shortened and delayed paradoxal sleep phase). Cpds. (I) are prepd. by reacting a reactive deriv. of 13-bromo-9, 10-dihydrolysergic acid (II) with a salt of an oxazolopyrrolopyrazine deriv. in the presence of a tert. organic base and an inert solvent. In an example, 13-bromo-9,10-dihydro-beta-ergocryptine is prepd. from 13-bromo-9,10-dihydrolysergic acid and 2-isopropyl-2-amino-5-(2-butyl)-3,6-dioxo-10b-hydroxy-octahydro-8- H-oxazolo 3,2-a pyrrolo 2,1-c pyrazine. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0026899-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-8100961-A1 |
| priorityDate | 1973-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 32.